<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35522161</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1470-8728</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>479</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Biochemical journal</Title>
          <ISOAbbreviation>Biochem J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>RIP1 post-translational modifications.</ArticleTitle>
        <Pagination>
          <StartPage>929</StartPage>
          <EndPage>951</EndPage>
          <MedlinePgn>929-951</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1042/BCJ20210725</ELocationID>
        <Abstract>
          <AbstractText>Receptor interacting protein 1 (RIP1) kinase is a critical regulator of inflammation and cell death signaling, and plays a crucial role in maintaining immune responses and proper tissue homeostasis. Mounting evidence argues for the importance of RIP1 post-translational modifications in control of its function. Ubiquitination by E3 ligases, such as inhibitors of apoptosis (IAP) proteins and LUBAC, as well as the reversal of these modifications by deubiquitinating enzymes, such as A20 and CYLD, can greatly influence RIP1 mediated signaling. In addition, cleavage by caspase-8, RIP1 autophosphorylation, and phosphorylation by a number of signaling kinases can greatly impact cellular fate. Disruption of the tightly regulated RIP1 modifications can lead to signaling disbalance in TNF and/or TLR controlled and other inflammatory pathways, and result in severe human pathologies. This review will focus on RIP1 and its many modifications with an emphasis on ubiquitination, phosphorylation, and cleavage, and their functional impact on the RIP1's role in signaling pathways.</AbstractText>
          <CopyrightInformation>Â© 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Varfolomeev</LastName>
            <ForeName>Eugene</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA 94110, U.S.A.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vucic</LastName>
            <ForeName>Domagoj</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0003-3614-8093</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA 94110, U.S.A.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biochem J</MedlineTA>
        <NlmUniqueID>2984726R</NlmUniqueID>
        <ISSNLinking>0264-6021</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051034">Inhibitor of Apoptosis Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051034" MajorTopicYN="N">Inhibitor of Apoptosis Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053422" MajorTopicYN="Y">Receptor-Interacting Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">RIP1</Keyword>
        <Keyword MajorTopicYN="Y">RIPK1</Keyword>
        <Keyword MajorTopicYN="Y">apoptosis</Keyword>
        <Keyword MajorTopicYN="Y">necroptosis</Keyword>
        <Keyword MajorTopicYN="Y">phosphorylation</Keyword>
        <Keyword MajorTopicYN="Y">ubiquitin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>10</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35522161</ArticleId>
        <ArticleId IdType="doi">10.1042/BCJ20210725</ArticleId>
        <ArticleId IdType="pii">231273</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
